GGrantIndex
Sort

39,280 grants matching leukemia

Genetic Analysis of the Zebrafish Somitogenesis Oscillator

$464,814
Scott A Holley · Yale University · R01 · FY2009 · HD

THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA

$464,800
Daisuke Nakada · Baylor College Of Medicine · R01 · FY2025 · CA

THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA

$464,800
Daisuke Nakada · Baylor College Of Medicine · R01 · FY2021 · CA

Targeting NSD1 in leukemia

$464,783
Tomasz Cierpicki · University Of Michigan At Ann Arbor · R01 · FY2021 · CA

Tumor maintenance and development in mouse models

$464,773
Harold E Varmus · Sloan-Kettering Inst Can Research · U01 · FY2008 · CA

Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

$464,700
Michael A Caligiuri · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA

An innovative integrated computational framework using gene signatures for patient stratification

$464,640
Chao Cheng · Baylor College Of Medicine · R01 · FY2023 · CA

DOXORUBICIN CARDIOMYOPATHY: MOLECULAR GENETICS &RESCUE

$464,568
University Of Southern California · R01 · FY2003 · HL

Targeting tumor-neural cell interactions to inhibit lung cancer brain metastasis

$464,516
Ann Marie Pendergast · Duke University · R01 · FY2023 · CA

Mechanisms of targeting cellular self-renewal in glioblastoma

$464,444
Hatem Sabaawy · Rbhs -Cancer Institute Of New Jersey · R01 · FY2020 · CA

Microchimerism as AlloImmunity

$464,427
J. Lee Lee Nelson · Fred Hutchinson Cancer Research Center · R01 · FY2015 · HL

Astrocytes in Retrovirus-Induced Spongiform Motor Neuron Disease

$464,412
William P Lynch · Northeast Ohio Medical University · R15 · FY2018 · NS

Phase I Clinical Trials of Novel Agents

$464,385
Naiyer A Rizvi · Sloan-Kettering Inst Can Research · U01 · FY2007 · CA

Dietary And Lifestyle Determinants Of Colon Cancer Recurrence and Survival

$464,372
Charles S Fuchs · Dana-Farber Cancer Inst · R01 · FY2016 · CA

Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms

$464,330
Gary W Reuther · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · HL

Clinical, Immunological and Genetic Analyses of ALPS and Related Disordrs

$464,319
Vemulkonda Rao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

The Role of CREB in Normal Myelopoiesis and Leukemogenesis

$464,302
Kathleen Miho Sakamoto · Stanford University · R01 · FY2012 · HL

NMR Studies of Retroviral Nucleic Acid Binding Proteins

$464,298
Michael F. Summers · University Of Maryland Baltimore County · R01 · FY2014 · GM

Flow Cytometric Evaluation of Biomarkers

$464,254
Maryalice Stetler-Stevenson · Division Of Basic Sciences - Nci · ZIC · FY2016 · CA

Prevalence, etiology, and clinical implications of low count monoclonal B-cell lymphocytosis (MBL)

$464,153
Susan L Slager · Mayo Clinic Rochester · R01 · FY2022 · AG

Using natural antibodies to improve vaccines

$464,084
John J Iacomini · Brigham And Women'S Hospital · R01 · FY2010 · AI

Glia maturation factor-gamma modulation of signaling pathways in macrophages

$464,033
Griffin Rodgers · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL

Preclinical Diagnostic Imaging of Amyloid

$464,016
Jonathan S Wall · University Of Tennessee Knoxville · R01 · FY2009 · DK

Mechanism of Therapy in high-risk AML

$463,996
Mohammad Azam · Cincinnati Childrens Hosp Med Ctr · R01 · FY2024 · CA

Targeted Lipopolyplexes for Oligonucleotide Delivery to AML

$463,970
Robert J. Lee · Ohio State University · R01 · FY2010 · CA